Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (January 2017)

26 slides from Enumeral Biomedical's investor presentation, Jan 9, 2017

  1. Slide 1: Enumeral Corporate Overview January 2017

    Enumeral Corporate Overview January 2017 OTCQB: ENUM Contact: Wael Fayad Chairman, President, and CEO 200 CambridgePark Drive Cambridge, MA 02140 [email protected] O: 617 - 500 - 1613

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward - looking statements that are based on the company’s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no representations about the accuracy of such statemen

  3. Slide 3: Overview

    Overview 3 Enumeral is an early stage biotechnology company utilizing a proprietary platform to transform biological complexity into powerful therapeutics in cancer, auto - immune, and other diseases * As of market close on January 3, 2017, unless otherwise noted. **Reflects results of Q4 2016 Warra

  4. Slide 4: A turnaround story poised for recovery

    A turnaround story poised for recovery The Past o Public trading on OTCQB through reverse merger in July 2014 o Raised $21.5 million in gross proceeds through sale of common stock plus warrants with anti - dilution protection o Unfocused growth strategy 4 Today o New management team in place with in

  5. Slide 5: Proprietary single cell microengraving technology reveals novel and valuable disease insights

    Proprietary single cell ‘ microengraving ’ technology reveals novel and valuable disease insights 5 Inventor of the technology Chris Love Associate Professor of Chemical Engineering at the Koch Institute for Integrative Cancer Research at MIT OTCQB: ENUM

  6. Slide 6: Proprietary, functionalized microwell chip

    Proprietary, functionalized microwell chip 6 OTCQB: ENUM

  7. Slide 7: Integrated system yields diverse types of data from one sample, at the single cell resolution

    Integrated system yields diverse types of data from one sample, at the single cell resolution 7 Isolate Rapid isolation of complex mixtures into single cells • Several chips per sample, 84,000 wells per chip, ~1 cell per well • Starting sample can be blood, tissue or cultured cells, or a mixture • S

  8. Slide 8: Understanding disease at the single cell level facilitates precision medicine

    Understanding disease at the single cell level facilitates precision medicine 8 Single cell analysis reveals new disease insights New disease insights translate into better therapeutics OTCQB: ENUM

  9. Slide 9: Platform technology is automated and validated

    Platform technology is automated and validated 9 Industrialized, automated & validated (2011 - 16) OTCQB: ENUM

  10. Slide 10: Types of questions platform can address

    Types of questions platform can address 10 “Can you help us understand why patients don’t respond to our drug?” “How do tumors develop resistance to our therapy?” “Can you isolate the B cells that are making the antibodies that are protecting the patient from disease?” “I’m interested in tumor - ass

  11. Slide 11: ENUM past & present

    ENUM past & present 2017: Unlocking full potential 11 Exclusive patent license SBIR Phase I award for technology development Tim3 , other antibodies discovered Differentiated, high affinity PD1 antibodies discovered Focused on securing partnerships to discover & develop novel therapeutics NCI SBIR P

  12. Slide 12: New leadership with intense focus and deep experience

    New leadership with intense focus and deep experience Wael Fayad • Appointed Chairman, President and CEO in September 2016 • Performance based compensation package • > 20 years of executive and business experience in pharma • Broad network and deep rolodex filled with senior executives in life scien

  13. Slide 13: Strengthened management team

    Strengthened management team 13 Wael Fayad Chairman, President and CEO Robert Schaub, Ph.D. Interim Head of Research and Development • 35 years scientific and executive leadership in pharma and biotech • Expert in translational drug discovery and development of small molecules and biologics • Author

  14. Slide 14: Experienced Board of Directors

    Experienced Board of Directors 14 Wael Fayad Chairman, President, and CEO Barry Buckland, Ph.D. Co - Founder; Director; Chairman, Scientific Advisory Board Robert J. Easton Director Allan Rothstein Director Paul J. Sekhri Director Robert L. Van Nostrand Director OTCQB: ENUM

  15. Slide 15: Expert Scientific Advisory Board

    Expert Scientific Advisory Board 15 Barry Buckland, Ph.D. Co - Founder; Director; Chairman, Scientific Advisory Board Giulio Draetta , M.D., Ph.D. Kai Wucherpfennig , M.D., Ph.D. OTCQB: ENUM

  16. Slide 16: Near term plan for recovery and growth

    Near term plan for recovery and growth • Secure collaborations to drive value • Build high value pipeline with potential to generate high partner interest in pre - clinical • Secure funding to support plan execution • Position company for growth or for other strategic options 16 OTCQB: ENUM

  17. Slide 17: Innovation and collaboration are cornerstone of our strategy

    Innovation and collaboration are cornerstone of our strategy 17 Solid foundation for future s uccess Discovery Development Development Candidate Collaboration Potential Across Value Chain • Use platform to build high value pipeline • Advance internal pipeline with improved capitalization • Explore t

  18. Slide 18: Significant value often recognized at pre-clinical stage

    Significant value often recognized at pre - clinical stage • Discovery and early stage biotechs can have high valuations ‒ CytomX Therapeutics (CTMX): ~$405M market cap* ‒ Regenxbio (RGNX): ~$504M market cap* • Lucrative deals recently made at the pre - clinical stage ‒ Pieris / Servier , January 20

  19. Slide 19: Enumeral antibody pipeline (partnering opportunities)

    Enumeral antibody pipeline (partnering opportunities) 19 PD - 1 Antibody ENUM 244C8 PD - 1 Antibody ENUM 388D4 TIM - 3 Antibody CD39 Lead generation Screening Optimization / Differentiation Pre - Clinical IND Enabling IND Other targets Development Candidate Platform provides a dditional c ollaborati

  20. Slide 20: Several near term milestones and catalysts

    Several near term milestones and catalysts • Deal flow – Exploring multiple options • Pre - clinical efficacy and safety data for lead PD - 1 product – Anticipated first quarter 2017 • In vitro and in vivo data with TIM - 3 program – Anticipated first quarter 2017 • Identify a new high value target

  21. Slide 21: Summing Up: What's New

    Summing Up: What’s New • New Management • Wael Fayad appointed Chairman, President, and CEO • Robert Schaub joined as Interim Head of R&D • New Direction • Create value through partnerships and strategic collaborations (including transformative in - licensing deals) • Exploit full potential of techn

  22. Slide 22: Thank You

    Thank You Contact: Wael Fayad Chairman, President, and CEO 200 CambridgePark Drive Cambridge, MA 02140 [email protected] O: 617 - 500 - 1613

  23. Slide 23: Appendix

    Appendix

  24. Slide 24: Collaborators provide external recognition of differentiated approach

    Collaborators provide external recognition of differentiated approach • MERCK : December 2014 collaboration with a leading immuno - oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cel

  25. Slide 25: Collaboration with MD Anderson Cancer Center – January 2016

    Collaboration with MD Anderson Cancer Center – January 2016 • Goal to Discover and Develop Novel Antibodies Against Specified Immunotherapy Targets – Utilizes Enumeral’s antibody discovery and patient - centric immune profiling platform – Leverages MD Anderson’s preclinical and development expertise

  26. Slide 26: License and Transfer Agreement with Pieris Pharmaceuticals – Spring 2016

    License and Transfer Agreement with Pieris Pharmaceuticals – Spring 2016 • Non - exclusive license under specified Enumeral patent rights and know - how to research, develop and market fusion proteins that comprise a moiety derived from Enumeral’s 388D4 anti - PD - 1 antibody linked to one or more P

Enumeral Biomedical Holdings — Investor Presentation (January 2017) on 6ix